Abstract Despite advances in detection and treatment, metastatic breast cancer (MBC) remains the second highest cause of cancer-related death for women in the United States. Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30 % of breast cancers and is associated with aggressive disease and, historically, with poorer outcome. The advent of trastuzumab, a monoclonal antibody to HER2, revolutionized the management of HER2-positive breast cancer (BC) in the metastatic and adjuvant settings. However, relapse despite adjuvant trastuzumab and resistance to trastuzumab in the metastatic setting remain substantial clinical problems for many patients with HER2-positive BC. As such, analyzing the mechanisms of trastuzumab resistance and developing new therapies to overcome it are research priorities. There has been progress, with the approval of three additional HER2-targeted agents in the last six years: lapatinib, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Other HER2-targeted therapies, including neratinib and afatinib, are in clinical development, and trials of novel agents such as heat shock protein-90 (HSP90) inhibitors, phosphatidylinositol-3-kinase (PI3K) inhibitors, and HER2-targeted vaccines, are in progress. In addition to developing new therapies, research is addressing several unique challenges in the management of HER2-positive MBC. In this article, we discuss advances in the treatment of HER2-positive MBC, focusing on novel HER2-targeted therapies and HER2-targeted agents recently approved by the United States Food and Drug Administration (FDA). We also address the management of brain metastases (BM) and hormone receptor (HR)-positive, HER2-positive MBC.
Introduction
Although BC outcomes have improved, MBC remains incurable, with 40,000 women expected to die from MBC in the United States in 2014 [1] . Approximately 25-30 % of BC is HER2-positive, which predicts more aggressive disease and response to HER2-targeted therapy [2] . HER2-positivity is defined by evidence of protein over-expression (measured by immunohistochemistry) and/or by evidence of gene amplification (measured by HER2 copy number or HER2/CEP17 ratio on in-situ hybridization) [3•] . Whereas HER2-positive BC was historically associated with poor prognosis [2, [4] [5] [6] , the development of HER2-targeted therapy beginning with trastuzumab, a monoclonal antibody to HER2, has resulted in dramatically improved overall survival (OS) for women with HER2-positive MBC and HER2-positive early-stage BC [7, 8] .
Despite the overall success of trastuzumab in treating HER2-positive MBC, approximately 70 % of patients become resistant to therapy within one year (secondary resistance) [9] and approximately 35 % do not respond to trastuzumab at all (de-novo resistance) [10, 11] . There are several potential mechanisms of resistance to trastuzumab therapy [9] , but there are no established biomarkers predictive of resistance to trastuzumab [12] . Continuation of trastuzumab beyond progression is beneficial for some patients [13] , however there is a clear need for other treatment options. Since 2007, three new HER2-targeted therapies (lapatinib, pertuzumab, and T-DM1) have been licensed by the FDA for use against HER2-positive MBC. Clinical trials evaluating the efficacy of newer HER2-targeted therapy and novel agents including tyrosine kinase inhibitors (TKIs), PI3K inhibitors, HSP90 inhibitors, and HER2-targeted vaccines are currently in progress (Table 1) . In this review we describe important developments in the treatment of HER2-positive MBC, ongoing research to improve outcomes for this subgroup of BC patients, and remaining challenges.
Molecular Biology of HER2
HER2 is a member of the epidermal growth factor receptor (EGFR or ErbB) family of receptor tyrosine kinases (TK), which includes four structurally related HER proteins-HER1 (EGFR, ErbB1), HER2, HER3 (ErbB3), and HER4 (ErbB4)-which all have a function in controlling cell growth, proliferation, and survival. HER2, which is encoded by the HER2 proto-oncogene on chromosome 17, is a 185-kDa membrane-spanning protein composed of a ligand-binding extracellular domain (ECD), an α-helical transmembrane segment, and an intracellular TK domain [41] [42] [43] . Homo-or heterodimerization of the HER receptors results in downstream intracellular signaling via canonical pathways that mediate cell growth and proliferation-the PI3K/mammalian target of rapamycin (mTOR) pathway, the Akt pathway, and the mitogen-activated protein kinase (MAPK) pathway. Unlike the other HER proteins, HER2 has no known ligand and occurs in a constitutively open conformation, making it the preferred partner for heterodimerization with other HER proteins. Formation of HER2 heterodimers (e.g. HER2/HER3) is more effective than formation of HER2 homodimers in promoting carcinogenesis by activating ligand-initiated intracellular signaling via the MAPK/PI3K/Akt/mTOR pathways [44] (Fig. 1) .
As discussed above, although trastuzumab has significantly improved outcomes for patients with HER2-positive MBC, the median duration of response is less than one year [45] . Determining the molecular mechanisms of resistance to trastuzumab has been difficult, but potential mechanisms of resistance include up-regulation of the PI3K pathway, accumulation of p95-HER2 (a truncated form of the HER2 receptor), and increased signaling from HER family receptors and the insulin growth factor 1 receptor (IGF-1R) [46] .
FDA-approved Therapy for HER2-positive MBC

Trastuzumab
Trastuzumab is a humanized monoclonal antibody that binds to domain IV of the juxta-membrane region of the ECD of HER2. Its mechanisms of action include inhibition of intracellular signaling, inhibition of angiogenesis, inhibition of ECD cleavage, increased intracellular HER2 degradation, and activation of antibody dependent cellular cytotoxicity (ADCC) [47] .
In a pioneering trial, Slamon et al. compared combined chemotherapy and trastuzumab with chemotherapy alone for first-line treatment of HER2-positive MBC. Findings revealed improved response rate (50 % vs 32 %; p<0.001), duration of response (9.1 months vs 6 months; p<0.001), time to progression (TTP) (7.4 months vs 5.6 months; p<0.001) and median overall survival (OS) (25.1 months vs 20.3 months, p=0.01) with the combination [7] . Since this trial, trastuzumab has been safely combined with several different chemotherapy agents for treatment of MBC [13] . In addition, several large adjuvant trials have revealed that addition of trastuzumab to chemotherapy for early-stage HER2-positive BC resulted in an approximately 50 % reduction in relapse and 30 % reduction in fatality [8, [48] [49] [50] [51] [52] [53] .
Cardiotoxicity, most frequently presenting as a decline in ejection fraction [54] , is the most significant toxicity associated with trastuzumab. Pre-clinical models of mice with cardiac-restricted deletion of HER2 revealed dilated cardiomyopathy [55] . On the basis of concern about cardiac toxicity during the initial clinical trials of trastuzumab, an independent cardiac review and evaluation committee was convened and their analysis confirmed a risk of heart failure, with the greatest incidence associated with concurrent administration of trastuzumab and anthracycline (27 %) and lower incidence associated with concurrent trastuzumab and taxanes (13 %) or trastuzumab alone (3-7 %) [56] . More recent data evaluating cardiac toxicity revealed asymptomatic declines in ejection fraction among approximately 25 % of patients and symptomatic declines in ejection fraction among approximately 4-5 % [48] [49] [50] [51] [52] [53] 57] .
Most women receiving trastuzumab for MBC will ultimately develop resistance. Preclinical data suggest that withdrawal of trastuzumab can result in rapid tumor cell re-growth [58, 59] , implying that trastuzumab-resistant tumors may still be dependent on HER2 TK-mediated signaling [10] . On this basis, the German Breast Group 26/Breast International Group 03-05 trial was designed to investigate whether trastuzumab should be continued beyond clinical progression [13] . Patients with HER2-positive MBC who had progressed on trastuzumab-based treatment were randomized to capecitabine monotherapy or to capecitabine plus trastuzumab. Although there was no difference in OS between the two groups, Abbreviations: mAB, monoclonal antibody; HER2, human epidermal growth factor receptor-2; ER, estrogen receptor; PR, progesterone receptor; AI, aromatase inhibitor, BM, brain metastases; MBC, metastatic breast cancer; EGFR, epithelial growth factor receptor; TKI, tyrosine kinase inhibitor; HER3, human epidermal growth factor receptor-3; HER2+, HER2-positive; HER1, human epidermal growth factor receptor-1; Hsp90i, Hsp90 inhibitor; VEGF, vascular endothelial growth factor; PI3K, phosphatidylinositol-3-kinase; mTOR, mammalian target of rapamycin; BC, breast cancer; HER4, human epidermal growth factor receptor-4 response rate was better for the capecitabine-plus-trastuzumab group (27 % vs 48.1 %, respectively, odds ratio, 2.50; p= 0.0115), supporting the practice of continuing trastuzumab beyond progression [13] .
Lapatinib
In 2004, Burris et al. reported that lapatinib, a dual EGFR/ErbB-2 TKI, inhibits tumor cell growth in vitro and in xenograft models of several human tumors [60] . Lapatinib blocks HER1 and HER2 TKs to the same extent, but its efficacy is limited to HER2-positive tumors [61, 62] . Unlike trastuzumab, lapatinib can cross the blood-brain barrier (BBB) and therefore has a therapeutic effect on intracranial metastases [63, 64] . In a pioneering trial, Geyer et al. randomized women with HER2-positive MBC who had previously received anthracycline, taxane, and trastuzumab therapy to capecitabine alone or to capecitabine plus lapatinib. Median TTP was longer for the combination group than for the monotherapy group (8.4 vs 4.4 months, p<0.001) and there was a trend toward improved OS with the combination (p=0.177). In addition, fewer patients presented with BM at first progression in the combination group [65, 66] . Burstein et al.
conducted a phase II trial of lapatinib monotherapy for heavily pretreated patients with MBC. No patients with HER2-negative disease responded; however in the HER2-positive cohort, three patients had a complete response (CR) and three patients had a partial response (PR), with median progressionfree survival (PFS) of 9.1 weeks and OS of 29.4 months. Of note, all the HER2-positive patients had previously received trastuzumab [67] . Pre-clinical studies noted a synergistic interaction between lapatinib and trastuzumab in ErbB2-positive cell lines, suggesting that dual HER2 blockade may be more effective than single agent blockade [61] . In addition, crossresistance between lapatinib and trastuzumab is incomplete, suggesting mechanisms of resistance to these drugs may differ [46] . The EGF104900 trial compared lapatinib alone with lapatinib plus trastuzumab for patients with HER2-positive, trastuzumab-refractory MBC. In this heavily pretreated population, a 4.5 month survival advantage was associated with dual HER2-targeted therapy [68, 69] . This finding led to future studies evaluating dual HER2-targeted therapy and suggested that HER2-targeted therapy alone (i.e. without chemotherapy) can be an option for HER2-positive MBC.
Targeted therapies and the HER2 pathway 
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4. Fig. 1 The human epidermal growth factor receptor (HER) family consists of four members: the epidermal growth factor receptor (EGFR), or HER1, and HER2, HER3, and HER4, which are transmembrane receptor tyrosine kinases that control cell growth survival, differentiation, migration, and other cellular responses. Of note, HER2 has no known ligand that induces its activity, and HER3 predominantly functions as a ligandactivated dimer partner for other members of the HER2 family. Activation of these receptors promotes tumor growth by inducing signaling through commonly used growth factor pathways, for example RAS/RAF/MEK and PI3K/AKT/mTOR. This figure shows sites of action of currently approved HER2-targeted therapies and of investigational HER2-targeted therapies. TRAS, trastuzumab; PER, pertuzumab; LAP, lapatinib; AFA, afatinib; NER, neratinib; PI3K, phosphatidylinositol-3-kinase; EVE, everolimus; mTOR, mammalian target of rapamycin; TEM, temsirolimus; P, phosphate; HSP, heat-shock protein; T-DM1, adotrastuzumab emtansine; i, inhibitor
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Unlike trastuzumab, lapatinib is rarely associated with cardiac toxicity [70] , a finding which may be explained by the fact that trastuzumab has a greater effect on calcium handling, reduction of HER2 protein levels, and increasing HER2 mRNA levels than does lapatinib [71] [72] [73] . Also, most studies of lapatinib were performed on women who had previously received trastuzumab, a group likely to have relatively normal cardiac function. Overall, the main toxicities associated with lapatinib are mild diarrhea and rash [74] .
Pertuzumab
Pertuzumab, a humanized monoclonal IgG antibody, binds to domain II of the HER2 ECD and inhibits HER2-dimerization [75, 76] . Pre-clinical trials revealed synergy between pertuzumab and trastuzumab [77] [78] [79] [80] [81] , a finding that was confirmed in a phase II trial evaluating pertuzumab and trastuzumab for patients with HER2-positive MBC who had progressed on previous trastuzumab-containing regimens [82] . Notably, the response rate for pertuzumab monotherapy is low [75] .
The pioneering CLEOPATRA trial evaluated first-line docetaxel and trastuzumab with either placebo or pertuzumab for 808 women with HER2-positive MBC. PFS was longer for the pertuzumab group (18.5 months vs 12.4 months, p <0.001). In the most recent analysis, median OS was 37.6 months for the placebo group and had not yet been reached for the pertuzumab group (p=0.0008) [83•, 84] . Trials evaluating pertuzumab in combination with other agents for first-line and later-line treatment of HER2-positive MBC are in progress [24, [85] [86] [87] . Pertuzumab is usually well tolerated, with the most common toxicity including rash, diarrhea, mucositis, and febrile neutropenia when it is combined with chemotherapy and trastuzumab [88] . Importantly, there is no increase in cardiotoxicity when pertuzumab is combined with trastuzumab and docetaxel compared with trastuzumab and docetaxel without pertuzumab [89, 90] .
Ado-trastuzumab Emtansine (T-DM1)
T-DM1 is a novel antibody-drug conjugate of a potent cytotoxic drug, DM1, a maytansine derivative, connected to trastuzumab via a stable linker, enabling targeted delivery of chemotherapy to HER2-positive cells [91] . The phase III EMILIA trial randomized patients previously treated with chemotherapy and trastuzumab to T-DM1 or to lapatinib plus capecitabine. Median PFS was 9.6 months with T-DM1 compared with 6.4 months with lapatinib plus capecitabine (p<0.001), and median OS at the second interim analysis crossed the stopping boundary for efficacy favoring T-DM1 (30.9 months vs 25.1 months, p<0.001) [92•] .
Although T-DM1 is associated with little toxicity, patients may develop thrombocytopenia and/or elevated liver enzymes [92•] . Studies still in progress further evaluating use of T-DM1 for HER2-positive MBC include the MARIANNE trial, assessing T-DM1 in combination with pertuzumab for firstline treatment, and the TH3RESA trial, which recently reported preliminary findings indicating improved PFS and overall response rate (ORR) with T-DM1 for patients who had received ≥ 2 lines of prior HER2-targeted therapy [87, 93] .
Investigational Agents
Several new agents are currently under investigation for treatment of HER2-positive MBC.
Small-molecule HER Family Tyrosine Kinase Inhibitors
Neratinib
Neratinib is an oral, irreversible inhibitor of HER1, HER2, and HER4 TK activity. On the basis of promising pre-clinical and phase I results [94, 95] , a single agent phase II study of neratinib for patients with advanced HER2-positive MBC was conducted. For patients who had previously been exposed to trastuzumab, median PFS was 22.3 weeks compared with 39.6 weeks for patients who were trastuzumab-naive. The most common grade III and/or IV adverse event was diarrhea, which occurred among 30 % of patients who had previously received trastuzumab and 13 % of patients who had not [96] . A small trial evaluating the combination of neratinib and capecitabine reported an impressive response rate of 50 % among patients previously treated with taxane and trastuzumab therapy [97] . Important ongoing trials are evaluating neratinib in multiple clinical settings, including in combination with temsirolimus for first-line treatment of HER2-positive MBC, in combination with capecitabine for previously treated patients, and, because neratinib crosses the BBB, for treatment of progressive BM for patients with HER2-positive MBC [29, 98, 99] . The most frequent adverse effects of neratinib include diarrhea and rash [96] .
Afatinib
Afatinib is an oral, irreversible pan-HER TKI which, similar to other small molecule anti-HER2 TKIs, crosses the BBB [100] . Phase I studies revealed that the most frequent toxicities associated with afatinib are diarrhea, nausea, vomiting, rash, and fatigue [101] . Early efficacy results for afatinib are promising, with a phase II study involving 41 patients who had progressed on trastuzumab demonstrating PR and stable disease (SD) in 11 % and 37 % of patients, respectively [102] . The Lux-Breast trials are currently evaluating afatinib in additional clinical settings. In the phase III Lux-Breast I trial, patients with HER2-positive MBC who have progressed on trastuzumab are randomized to vinorelbine plus trastuzumab or to vinorelbine plus afatinib [103] . The Lux-Breast II trial is evaluating the efficacy of afatinib monotherapy for patients who have previously progressed on trastuzumab and/or lapatinib [104] . The Lux-Breast III trial is evaluating afatinib monotherapy or afatinib plus vinorelbine compared with the investigators' choice of treatment for patients with HER2-positive MBC and progressive BM who have previously progressed on trastuzumab or lapatinib-based therapy [105] . In addition to the Lux-Breast trials, afatinib is being evaluated by other trials in combination with endocrine therapy [106] , and in combination with trastuzumab or lapatinib [107, 108] .
Investigational Antibodies
MM-111
MM-111 is a bio-specific antibody, an artificial protein composed of fragments of two different monoclonal antibodies, which can bind two different kinds of antigen [109] . MM-111 forms a trimeric complex with HER2 and HER3, resulting in inhibition of HER3 signaling. In preclinical models, MM-111 had anti-tumor activity against tumors dependent on HER2 overexpression [110] . It has been proposed that blockade of both HER2 and HER3 may be a more effective method of treating HER2-amplified tumors than HER2 blockade alone [111] . A phase I trial of MM-111 and trastuzumab is in progress for patients with trastuzumab-refractory HER2-positive MBC [112] . In addition, NCT01304784 is a phase I and pharmacological study of MM-111 in combination with several treatment regimens for patients with advanced HER2-positive solid tumors [34] .
PI3K Inhibitors and mTOR Inhibitors
Somatic mutations which activate the PI3K-Akt-mTOR pathway are present in >50 % of BC, providing a sound rationale for evaluating inhibitors of this pathway for BC treatment [113] . Because PI3K is downstream from HER2 and mTOR is downstream from PI3K, targeting this pathway may be an important step in overcoming trastuzumab resistance in HER2-positive BC. The PI3K inhibitors under development are classified by mechanism of action, i.e. pure PI3K inhibitors, compounds which block both PI3K and mTOR (dual inhibitors), pure catalytic mTOR inhibitors, and inhibitors which block Akt [114] . XL147 selectively inhibits the class I PI3K family and, on the basis of promising pre-clinical efficacy, has been evaluated in phase I clinical trials, in which it had an acceptable safety profile. On the basis of encouraging preclinical data, a phase I and II study of XL147 in combination with trastuzumab or paclitaxel and trastuzumab was conducted among patients with HER2-positive MBC who had progressed on a previous trastuzumab-containing regimen; results are awaited [115] . The pan-class-1 PI3K inhibitor, BKM120, is also under investigation in a phase I trial evaluating its efficacy in combination with trastuzumab for patients with advanced HER2-positive BC who have progressed on a trastuzumab-based regimen [116] .
The largest trials evaluating mTOR inhibition of HER2-positive MBC include the BOLERO-1 and BOLERO-3 trials. The phase III BOLERO-1 trial, which has completed accrual, compares paclitaxel and trastuzumab with or without everolimus for first-line treatment of women with HER2-positive MBC [117] . Preliminary results of the BOLERO-3 trial, evaluating vinorelbine and trastuzumab with or without everolimus for treating HER2-positive MBC which has progressed on taxanes and trastuzumab therapy, were presented in 2013 [118] . Median PFS for the everolimus group was seven months, compared with 5.78 months for the placebo group (HR 0.78, 95 % CI 0.65, 0.95; p=0.0067). OS data are not yet mature. Although the results of BOLERO-3 are proof of principle for the use of mTOR inhibition to overcome trastuzumab resistance, it is uncertain that these results will be clinically significant given the small increase in PFS and the additional toxicity. Other phase I and II trials are investigating the efficacy of PI3K inhibitors as monotherapy or in combination with endocrine therapy or HER2-targeted therapy [113] . Whether all patients with HER2-positive MBC or solely those with PI3K mutations derive benefit from these agents remains to be confirmed [114] .
HSP90 Inhibitors
The chaperone protein HSP90 interacts with client proteins in the cell cycle, including HER2, and potentiates the action of antineoplastic agents including trastuzumab [119] . Preclinical studies suggest that the combination of HSP90 inhibitors and trastuzumab can overcome resistance to trastuzumab monotherapy. Several HSP90 inhibitors have been evaluated in phase I and II trials; however, the development of some of these compounds, including geldanamycin, has been limited because of toxicity [120] . Tanespimycin/17-AAG is a derivative of geldanamycin, which has similar efficacy but reduced toxicity. A phase II trial conducted on patients with HER2-positive MBC revealed promising results, with an ORR of 22 % and a clinical benefit rate (CBR) of 59 % [121] . The most common toxicities was grade I and included diarrhea, nausea, fatigue, and headaches, but development of tanespimycin/17-AAG was halted in 2008 because of production problems. Alvespimycin is a water-soluble derivative of geldanamycin. A phase I trial of this agent combined with trastuzumab among patients with HER2-positive MBC noted an ORR of 6.25 % with SD observed in 18.75 %; however, concerns regarding ocular toxicity precluded further clinical development [122] . Retaspimycin in combination with trastuzumab was evaluated in a phase II trial on a similar patient population and had modest clinical activity with an ORR of 5 % and SD observed in 70 %. The most common toxicities were was grade I and II, including fatigue (49 %), nausea (31 %), and diarrhea (23 %) [123] . Another HSP90 inhibitor, ganetespib, is under evaluation for first-line treatment of patients with HER2-positive MBC in a phase II trial (Enchant) [124] . A phase I trial looked at four different dose levels of ganetespib in 30 patients with advanced HER2-positive breast cancer. Antitumor activity was noted in two patients who had a PR. Dose limiting toxicities were grade III diarrhea and grade IV aphasia [125] . AUY922 is a potent small-molecule synthetic HSP90 inhibitor with promising clinical activity. A phase Ib and II trial is in progress to evaluate the combination of AUY922 and trastuzumab for patients with HER2-positive MBC who have progressed on previous trastuzumab-based therapy [126] .
Anti-angiogenic Agents
Bevacizumab
Bevacizumab, a recombinant humanized monoclonal antibody, targets vascular endothelial growth factor (VEGF) and inhibits angiogenesis, which is necessary for tumor growth and survival. HER2 overexpression is associated with increased VEGF expression, and pre-clinical evidence suggests that the HER2 and VEGF signaling pathways are linked in human BC [127] , thus providing the rationale for evaluating anti-angiogenic therapy for HER2-positive BC. On the basis of promising phase I and II results for the combination of bevacizumab with chemotherapy and HER2-targeted therapy [128, 129] , the AVEREL study compared bevacizumab, docetaxel, and trastuzumab with trastuzumab and docetaxel alone for first-line treatment of HER2-positive MBC [130] . Disappointingly, no difference in PFS or OS was observed on addition of bevacizumab. Further evidence of the lack of benefit of adding anti-angiogenic therapy to chemotherapy plus trastuzumab comes from the recently presented findings of the adjuvant BETH trial in which bevacizumab did not confer additional benefit when added to chemotherapy and trastuzumab for patients with HER2-positive early BC [131] .
Vaccine Therapy
On the basis of the observation that patients can spontaneously develop anti-HER2 specific immunity with high humoral and cellular immunity, HER2 is one of the most suitable targets for immunotherapy in BC [132] . Types of vaccine therapy currently under evaluation include peptidebased, protein-based, DNA-based, whole tumor cell-based, and dendritic cell-based compounds. A phase I and II study evaluated the combination of trastuzumab and an HER2 peptide-based vaccine for 22 previously treated patients with HER2-positive MBC [133] . Treatment was well tolerated, with a median PFS of 17.7 months, which compared favorably with results achieved with standard therapy for this population. E75 is an immunogenic peptide from the HER2/neu protein, which is strongly expressed in BC [134] . Benavides et al. studied the combination of trastuzumab and the E75 vaccine, which was safe and immunologically beneficial [135] . A Phase I trial assessed the combination of an allogeneic HER2-positive granulocyte-macrophage colony stimulating factor (GM-CSF) secreting breast tumor vaccine with trastuzumab and cyclophosphamide. Twenty-two patients with HER2-positive MBC were enrolled and no dose limiting toxicity (DLT) was noted; the CBR at six and 12 months was 50 % and 35 %, respectively [136] . Another trial evaluated the combination of a DNA vaccine, low-dose IL-2, and GM-CSF in combination with trastuzumab for eight patients with HER2-positive MBC; low toxicity and a strong therapeutic antibody response were noted, and two patients are long-term survivors [137] . Although available immunotherapy is safe and tolerable, there have been no direct comparisons with standard therapy for HER2-positive BC. Therefore, it remains to be seen whether meaningful clinical responses, as defined by an improvement in OS compared with that obtained by standard therapy for HER2-overexpressing BC, will be observed [132] .
Predictive Biomarkers for HER2-targeted Therapy
Biomarker analysis of patients with HER2-positive MBC has failed to identify any marker that enables better refinement of therapy than HER2 itself. However, data suggest that the prognosis of patients with HER2-positive MBC treated with trastuzumab is significantly worse for patients with PI3KCA mutations [138] . Therefore PI3KCA mutational status may confer poor prognosis for patients with HER2-positive MBC, and patients may be suitable candidates for clinical trials of HER2-targeted agents in combination with PI3K inhibitors or mTOR inhibitors [139•] . A prospective analysis of 737 patients enrolled in the GeparSixto and GeparQuinto trials noted that patients with PI3KCA mutant, HER2-positive, HR-positive BC are resistant to chemotherapy and dual HER2-targeted therapy, which implies that PI3KCA mutational status is also predictive of response to treatment [140] . Biomarker analysis from EMILIA revealed that patients with PI3KCA mutations treated with lapatinib and capecitabine had inferior median PFS and OS; however, the presence of PI3KCA mutations did not significantly affect outcome for patients treated with T-DM1 [141] .
Special Clinical Considerations in the Management of HER2-positive MBC
Brain Metastases
Unfortunately, BM occur in approximately 30-55 % of patients with HER2-positive MBC [142] , with data suggesting that BM may be particularly common among patients previously treated with adjuvant trastuzumab for early-stage HER2-positive BC [143] . Small molecule TKIs which cross the BBB are a potentially promising new addition to standard therapy for BM in HER2-positive MBC patients. For example, the single-group, multi-center phase II LANDSCAPE trial evaluating the combination of capecitabine and lapatinib for patients with HER2-positive MBC and untreated BM reported a 65.9 % objective CNS response rate [144] . An ongoing clinical trial is evaluating the efficacy of neratinib for patients with HER2-positive BM (NCT01494662) [29] .
Management of Hormone Receptor-positive, HER2-positive MBC
The role of endocrine therapy for treatment of HR-positive, HER2-positive MBC is not well defined, because the decision is often made to use chemotherapy plus HER2-targeted therapy, because of an aggressive clinical course. However, preclinical results suggest that HER2-targeted therapy can overcome endocrine resistance in HR-positive, HER2-positive BC [145] . The TAnDEM study evaluated anastrozole and trastuzumab versus anastrozole alone for treatment of postmenopausal women with HR and HER2-positive MBC [146] . Although use of the combination resulted in improved median PFS (5.6 versus 3.8 months, p=0.006), no OS benefit was noted, possibly because 70 % of patients in the anastrozolealone group crossed over to trastuzumab after progression. Lapatinib has also been evaluated in combination with endocrine therapy on the basis that cross-talk between the EGFR and estrogen-receptor pathways can cause endocrine resistance. In a phase II trial on post-menopausal, HR-positive women with HER2-positive MBC, addition of lapatinib to letrozole significantly reduced the risk of disease progression compared with letrozole alone (median PFS 8.2 vs 3.0 months) [147] .
Conclusion
There has been rapid progress in the treatment of HER2-positive MBC, and it is likely that further practice-changing developments will occur. Dual HER2-targeted therapy has been a powerful addition to the treatment options, but appropriate combination and sequencing of the newer agents with more established HER2-targeted therapy is still not fully defined. However, the American Society of Clinical Oncology recently released clinical guidelines based on currently available data which provide recommendations for treatment of HER2-positive MBC in first and later lines of care using the array of currently available HER2-targeted therapies [148•] . To make further progress, identification of predictive biomarkers will be crucial in further refining treatment options and more knowledge of mechanisms of resistance to trastuzumab will help identify new targets. Unique challenges of managing HER2-positive MBC include the treatment of HER2-positive BM, and management options for patients who have HR-positive and HER2-positive MBC. Several compounds are in different stages of clinical development, and it remains to be seen which of these will affect the swiftly changing therapeutic options for HER2-positive MBC.
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